Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance
Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.